Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Radiotherapy (RT) and concomitant/adjuvant therapy with temozolomide (Temodar) is a common treatment regimen for children and adults with glioma. Although temozolomide is generally well tolerated with temporary myelosuppression as the primary dose-limiting toxicity, irreversible bone-marrow aplasia after treatment with temozolomide has been reported. We report the case of an adolescent patient with a high-grade glioma who, after >2 years of event-free survival, underwent successful bone marrow transplantation for treatment of temozolomide-induced severe aplastic anemia (SAA).
Morris
E Brannon
EB
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. brannon.morris@stjude.org
Kasow
Kimberly
K
Reiss
Ulrike
U
Ellison
David
D
Broniscer
Alberto
A
D000293:Adolescent; D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000601:surgery*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D016026:Bone Marrow Transplantation / Q000379:methods*; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide